19.3% Weight Loss at Week 48: Phase Ⅲ Data of Olatorepatide, Hansoh's Dual‑Biased GLP‑1/GIP Agonist, Presented at EASD

Hansoh Pharma announced its participation at the European Association for the Study of Diabetes annual meeting in Milan, held September 28 to October 2, 2026. The release references the company's self-developed dual-biased GLP-1/GIP therapy, but the provided article text does not include clinical data, regulatory updates, financial details, or commercialization guidance.